Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17174458 | RESIDENCE STRUCTURES AND RELATED METHODS | February 2021 | January 2022 | Allow | 60 | 2 | 1 | Yes | No |
| 17247708 | METHODS FOR ADMINISTERING ARIPIPRAZOLE | December 2020 | May 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17126786 | RESIDENCE STRUCTURES AND RELATED METHODS | December 2020 | March 2021 | Allow | 3 | 1 | 0 | Yes | No |
| 17126835 | RESIDENCE STRUCTURES AND RELATED METHODS | December 2020 | March 2022 | Allow | 15 | 2 | 1 | No | No |
| 17117599 | PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVATED CARBON | December 2020 | March 2023 | Allow | 27 | 1 | 0 | No | No |
| 17116202 | ROCKET-SHAPED RECTAL SUPPOSITORY | December 2020 | June 2022 | Abandon | 18 | 0 | 1 | No | No |
| 17113785 | USE OF HYDROGEL COMPOSITION FOR ALLEVIATING DEGENERATIVE JOINT AND TENDON TEAR | December 2020 | March 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17111895 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG | December 2020 | October 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17057924 | SUSTAINED RELEASE INJECTABLE FORMULATION CONTAINING A POLY L LACTIC ACID FILLER AND A HYALURONIC ACID FILLER CONJUGATE AND A METHOD FOR PREPARING THE SAME | November 2020 | September 2023 | Allow | 34 | 2 | 0 | No | No |
| 17077856 | CONTINUOUS MICROPARTICLE MANUFACTURE | October 2020 | March 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17072895 | NANOSCALE METAL-ORGANIC FRAMEWORKS FOR ENHANCED TUMOR CHEMORADIATION | October 2020 | November 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16974068 | Method and composition for the reduction of viral replication, duration and spread of the COVID-19 and the Flu | September 2020 | February 2023 | Allow | 28 | 2 | 1 | Yes | No |
| 17022062 | CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE | September 2020 | March 2024 | Allow | 42 | 2 | 1 | Yes | Yes |
| 17008880 | LABILE ESTERS OF AGROCHEMICALS FOR CONTROLLED RELEASE AND REDUCTION OF OFF-SITE MOVEMENT | September 2020 | June 2022 | Allow | 21 | 0 | 1 | No | No |
| 16976906 | NANOPARTICLE COMPOSITIONS | August 2020 | March 2023 | Abandon | 30 | 1 | 1 | No | No |
| 16976030 | METHOD FOR ACCELERATING WOUND HEALING | August 2020 | February 2023 | Abandon | 30 | 2 | 0 | Yes | No |
| 17003361 | MEDICAL DEVICES FOR CONTINUOUS DELIVERY OF THERAPEUTIC AGENTS | August 2020 | January 2022 | Allow | 17 | 2 | 1 | Yes | No |
| 17000450 | SYSTEMS AND METHODS FOR DECRYSTALLIZATION OF URIC ACID | August 2020 | May 2023 | Abandon | 32 | 1 | 1 | No | No |
| 16995020 | LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED ADMINISTRATION OF DRUGS | August 2020 | May 2023 | Allow | 33 | 3 | 0 | Yes | No |
| 16970049 | Methods and Compositions for the Treatment of Pain and/or Inflammation | August 2020 | October 2023 | Allow | 38 | 3 | 1 | Yes | No |
| 16992036 | NANOPARTICLE COMPOSITIONS | August 2020 | December 2021 | Allow | 16 | 3 | 1 | Yes | No |
| 16983741 | COMPOSITIONS AND METHODS FOR DIAGNOSING OR TREATING NEUTROPHIL-MEDIATED INFLAMMATORY DISEASE | August 2020 | June 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16966623 | HETEROARYL SULFONAMIDE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISMS | July 2020 | January 2023 | Abandon | 30 | 1 | 0 | No | No |
| 16966683 | APPARATUS AND METHOD FOR PROTECTING NEURONS AND REDUCING INFLAMMATION AND SCARRING | July 2020 | July 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16945686 | AQUATIC HERBICIDE HAVING NON-HERBICIDAL FUNCTIONAL INGREDIENTS | July 2020 | April 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16961496 | METHODS, POLYMER-CONTAINING FORMULATIONS, AND POLYMER COMPOSITIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERS | July 2020 | December 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16909995 | Topical Serum for Treating Damaged Plants | June 2020 | September 2023 | Abandon | 39 | 2 | 1 | No | Yes |
| 16907707 | COMPOSITE DURA SUBSTITUTE IMPLANT | June 2020 | September 2021 | Allow | 15 | 1 | 0 | No | No |
| 16955659 | W/O/W MICROEMULSIONS FOR OCULAR ADMINISTRATION | June 2020 | September 2023 | Allow | 39 | 3 | 1 | Yes | No |
| 16772204 | SOLID LIPID NANOPARTICLE FOR INTRACELLULAR RELEASE OF ACTIVE SUBSTANCES AND METHOD FOR PRODUCTION THE SAME | June 2020 | July 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16899447 | RESIDENCE STRUCTURES AND RELATED METHODS | June 2020 | August 2021 | Allow | 15 | 2 | 0 | Yes | No |
| 16897408 | OPHTHALMIC PRODUCT WITH CORNEA REPAIR FUNCTION | June 2020 | July 2023 | Abandon | 37 | 3 | 1 | No | No |
| 16770924 | TISSUE REPAIR | June 2020 | November 2022 | Allow | 29 | 2 | 1 | No | No |
| 16894235 | SILVER NANOPARTICLES IMPREGNATED COVERS FOR ELECTRONIC DEVICES TO COMBAT NOSOCOMIAL INFECTIONS | June 2020 | May 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16768928 | COMPOSITION HAVING EXCELLENT PERMEABILITY TO WATER VAPOUR | June 2020 | January 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 16765044 | COSMETIC HAIR PREPARATION | May 2020 | March 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16868291 | STABILIZED PROTEIN GEL PREPARATION | May 2020 | January 2023 | Abandon | 32 | 2 | 0 | Yes | No |
| 16868339 | SUSTAINED RELEASE COMPOSITION USING BIOBASED BIODEGRADABLE HYPERBRANCHED POLYESTERS | May 2020 | February 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 16857044 | GREEN BIN ODOR REDUCTION COMPOSITION AND USE THEREOF | April 2020 | November 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16842341 | IMMUNE-MODIFYING NANOPARTICLES FOR THE TREATMENT OF INFLAMMATORY DISEASES | April 2020 | September 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16753727 | Microbiocidal Picolinamide Derivatives | April 2020 | November 2022 | Allow | 32 | 2 | 0 | Yes | No |
| 16873379 | Methods for treatment of lung damage and for inhibition of lung fibrosis | April 2020 | July 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16832700 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANTS AND METHODS OF USE THEREOF | March 2020 | April 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16830789 | METHODS FOR FIXING HAIR AND SKIN | March 2020 | May 2022 | Allow | 25 | 2 | 0 | Yes | No |
| 16829607 | METHOD OF TREATING ACID-BASE DISORDERS | March 2020 | January 2024 | Abandon | 45 | 2 | 1 | No | Yes |
| 16826938 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | March 2020 | January 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16813044 | PALONOSETRON FORMULATIONS AND USES THEREOF | March 2020 | July 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16808931 | Methods, Compositions and Articles for Improving Joint Lubrication | March 2020 | November 2023 | Abandon | 44 | 2 | 1 | No | No |
| 16643538 | IMMUNMODULATION FOR PREVENTION OF POOR HEALING OF MUSCULOSKELETAL INJURIES IN COMPROMISED PATIENTS | February 2020 | February 2023 | Abandon | 35 | 2 | 1 | No | No |
| 16642740 | STENTS | February 2020 | June 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16640758 | ANTIMICROBIAL COATING | February 2020 | May 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16790009 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF SURGICAL SITE INFECTIONS | February 2020 | July 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16747928 | CLAY PRODUCT AND USES THEREOF | January 2020 | January 2022 | Allow | 24 | 1 | 1 | No | No |
| 16631716 | BIODEGRADABLE BLOCK COPOLYMER DRUG DELIVERY COMPOSITION | January 2020 | June 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16631586 | BIODEGRADABLE BLOCK COPOLYMER DRUG DELIVERY COMPOSITION | January 2020 | January 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 16630779 | POLYMER FILMS WITH ANTIMICROBIAL AGENTS | January 2020 | September 2022 | Abandon | 32 | 1 | 1 | Yes | No |
| 16725444 | ORTHOPEDIC IMPLANT HAVING A CRYSTALLINE GALLIUM-CONTAINING HYDROXYAPATITE COATING AND METHODS FOR MAKING THE SAME | December 2019 | June 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16622366 | Selective RARy Ligand-loaded nanoparticles for manipulation of targeted bone growth | December 2019 | July 2023 | Allow | 44 | 3 | 1 | No | No |
| 16709832 | BIOMIMETIC, MOLDABLE, SELF-ASSEMBLED CELLULOSE SILICA-BASED TRIMERIC HYDROGELS AND THEIR USE AS VISCOSITY MODIFYING CARRIERS IN INDUSTRIAL APPLICATIONS | December 2019 | December 2022 | Allow | 36 | 3 | 0 | No | No |
| 16706409 | EMULSIFIED FATTY ACIDS | December 2019 | June 2020 | Allow | 6 | 1 | 0 | Yes | No |
| 16619133 | RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIA | December 2019 | April 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16693149 | RESIDENCE STRUCTURES AND RELATED METHODS | November 2019 | May 2020 | Allow | 6 | 1 | 0 | Yes | No |
| 16693121 | RESIDENCE STRUCTURES AND RELATED METHODS | November 2019 | May 2020 | Allow | 6 | 1 | 0 | Yes | No |
| 16680896 | NATURAL STYLING GEL WITH CARRAGEENAN AND A FILM FORMER | November 2019 | December 2022 | Abandon | 37 | 4 | 0 | No | No |
| 16679044 | COMPOSITIONS AND PRODUCTS FOR USE IN THE TREATMENT OF BONE FRACTURES AND DEFECTS | November 2019 | August 2022 | Allow | 34 | 2 | 1 | No | No |
| 16593941 | METHOD OF SOFT TISSUE AUGMENTATION | October 2019 | May 2022 | Allow | 32 | 2 | 0 | Yes | No |
| 16571933 | METHODS FOR TREATING RELAXED HAIR | September 2019 | July 2021 | Allow | 22 | 1 | 0 | No | No |
| 16493963 | PHARMACEUTICAL COMPOSITIONS HAVING HIGH DRUG LOADINGS OF MEDIUM CHAIN TRIGLYCERIDES AND METHODS RELATED THERETO | September 2019 | September 2022 | Allow | 36 | 2 | 1 | Yes | No |
| 16556678 | KERATIN TREATMENT FORMULATIONS AND METHODS | August 2019 | September 2021 | Abandon | 25 | 1 | 0 | Yes | No |
| 16602191 | SYNERGISTIC COMPOSITIONS TO STIMULATE THE SYNTHESIS OF HUMAN LUNG AND SINUS SURFACTANTS TO DECREASE COUGHING, INCREASE FEV-1/FVC RATIOS, DECREASE LUNG FIBROSIS, BY INCREASING APOPTOSIS OF MYOFIBROBLASTS | August 2019 | February 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16539653 | METHOD FOR MAKING A TRANSDERMAL FENTANYL PATCH WITH EVEN DRUG CRYSTAL DISTRIBUTION | August 2019 | August 2022 | Abandon | 36 | 2 | 1 | Yes | No |
| 16532155 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | August 2019 | November 2022 | Abandon | 39 | 6 | 0 | No | No |
| 16532120 | EFFICIENT AQUEOUS ENCAPSULATION AND CONTROLLED RELEASE OF BIOACTIVE AGENTS | August 2019 | October 2022 | Allow | 39 | 2 | 1 | No | No |
| 16524664 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | July 2019 | April 2020 | Allow | 9 | 1 | 1 | Yes | No |
| 16520650 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | July 2019 | September 2021 | Abandon | 26 | 2 | 1 | Yes | No |
| 16512231 | NON-INVASIVE OCULAR DRUG DELIVERY DEVICES | July 2019 | June 2022 | Abandon | 35 | 2 | 0 | No | No |
| 16510355 | COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESION | July 2019 | February 2023 | Abandon | 43 | 2 | 1 | Yes | No |
| 16459700 | Calcium Alginate Dosage Formulations, and Methods of Making and Using Thereof | July 2019 | January 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16458273 | HYDROGEL CAPSULES AND PROCESS FOR PREPARING THE SAME | July 2019 | September 2021 | Allow | 26 | 1 | 1 | No | No |
| 16436636 | COLLAGEN-BASED THERAPEUTIC DELIVERY SYSTEMS | June 2019 | August 2022 | Abandon | 38 | 2 | 1 | No | No |
| 16429417 | CO-FORMULATIONS OF BIFENTHRIN WITH HIGH-MELTING CROP PROTECTION AGENTS FOR USE WITH LIQUID FERTILIZERS | June 2019 | February 2022 | Abandon | 32 | 2 | 0 | No | No |
| 16415582 | Herbicide composition for use in killing one or more plant species | May 2019 | March 2022 | Abandon | 34 | 1 | 1 | No | No |
| 16349186 | BODY TEMPERATURE-TRIGGERED, IN SITU FORMING BIOMATERIALS AND DEVICES | May 2019 | July 2023 | Allow | 50 | 4 | 1 | Yes | No |
| 16401681 | MEDICAMENT-CONTAINING HOLLOW PARTICLE | May 2019 | June 2023 | Abandon | 50 | 4 | 0 | No | No |
| 16395956 | METHOD FOR PREPARING ELECTROSPUN FIBERS WITH A HIGH CONTENT OF A BIOADHESIVE SUBSTANCE | April 2019 | May 2021 | Allow | 25 | 2 | 0 | Yes | Yes |
| 16394647 | TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE | April 2019 | July 2021 | Abandon | 27 | 1 | 0 | No | No |
| 16379727 | RESIDENCE STRUCTURES AND RELATED METHODS | April 2019 | October 2019 | Allow | 6 | 0 | 1 | Yes | No |
| 16378027 | TEAT PACK MATERIAL FOR LACTATING LIVESTOCK, KIT FOR FORMING TEAT PACK FOR LACTATING LIVESTOCK, AND METHOD FOR PREVENTING MASTITIS IN LACTATING LIVESTOCK | April 2019 | May 2022 | Abandon | 38 | 3 | 0 | Yes | No |
| 16338962 | IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE | April 2019 | October 2023 | Abandon | 55 | 3 | 1 | No | No |
| 16372006 | PHARMACEUTICAL COMPOUNDING METHODS AND SYSTEMS | April 2019 | January 2021 | Allow | 21 | 3 | 1 | Yes | No |
| 16369544 | TOPICAL PREPARATIONS COMPRISING POLYALKOXYLATED POLYOLS POLYESTER WITH GUERBET ACID | March 2019 | September 2021 | Abandon | 30 | 1 | 1 | No | No |
| 16369663 | LIQUID THICKENER COMPOSITION COMPRISING POLYALKOXYLATED POLYOLS POLYESTER FOR PERSONAL CARE, DERMATOLOGICAL, AND PHARMACEUTICAL PREPARATIONS HAVING GUERBET ACID MOIETIES | March 2019 | September 2021 | Abandon | 30 | 1 | 1 | No | No |
| 16332459 | LOW MOLECULAR WEIGHT KERATIN HYDROLYSATES | March 2019 | December 2022 | Abandon | 45 | 2 | 1 | No | No |
| 16297125 | PEMETREXED FORMULATIONS | March 2019 | April 2024 | Abandon | 60 | 6 | 0 | Yes | No |
| 16294885 | ENHANCED DELIVERY OF IMMUNOSUPPRESSIVE DRUG COMPOSITIONS FOR PULMONARY DELIVERY | March 2019 | March 2022 | Allow | 36 | 2 | 0 | No | No |
| 16289491 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE | February 2019 | June 2021 | Abandon | 27 | 1 | 0 | No | No |
| 16277516 | RESIDENCE STRUCTURES AND RELATED METHODS | February 2019 | September 2019 | Allow | 7 | 1 | 1 | Yes | No |
| 16256709 | SOFT GELATIN ENCAPSULATED PHARMACEUTICAL COMPOSITION OF CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID IN FREE ACID FORM AND CIS-7,10,13,16,19-DOCOSAPENTAENOIC ACID IN FREE ACID FORM | January 2019 | June 2021 | Abandon | 29 | 0 | 1 | No | No |
| 16245960 | METHODS AND POLYMER-CONTAINING FORMULATIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERS | January 2019 | June 2021 | Abandon | 29 | 4 | 1 | Yes | Yes |
| 16221771 | CITRUS BASED ANTIMICROBIAL SOLUTION | December 2018 | September 2021 | Abandon | 33 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VANHORN, ABIGAIL LOUISE.
With a 18.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VANHORN, ABIGAIL LOUISE works in Art Unit 1616 and has examined 1,013 patent applications in our dataset. With an allowance rate of 41.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner VANHORN, ABIGAIL LOUISE's allowance rate of 41.9% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by VANHORN, ABIGAIL LOUISE receive 2.59 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by VANHORN, ABIGAIL LOUISE is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +23.4% benefit to allowance rate for applications examined by VANHORN, ABIGAIL LOUISE. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 16.9% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 24.0% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 60.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 51% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 48.4% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 51.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 57.7% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.6% of allowed cases (in the 72% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.7% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.